| Biological Sciences | 2021-2025 | 101 | CN 39 | 99.91 |
| Medical and Health Sciences | 2021-2025 | 235 | CN 23 | 99.96 |
| Immunology | Lifetime | 803 | CN 23 | 97.40 |
| Cancer Research | Lifetime | 647 | CN 52 | 95.62 |
| Medical Genetics | Lifetime | 752 | CN 15 | 91.27 |
| Immunology | 2021-2025 | 7 | CN 1 | 99.78 |
| Cancer Research | 2021-2025 | 17 | CN 7 | 99.34 |
| Oncology | 2021-2025 | 85 | CN 8 | 99.46 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 117 | CN 15 | 99.21 |
| Molecular Biology | 2021-2025 | 250 | CN 107 | 98.89 |
| Medical Genetics | 2021-2025 | 95 | CN 2 | 96.74 |
| Epidemiology | 2021-2025 | 509 | CN 54 | 95.35 |
| Medical Physiology | 2021-2025 | 450 | CN 30 | 93.58 |
| Hematology | 2021-2025 | 413 | CN 13 | 71.20 |
| Ferroptosis and cancer prognosis | Lifetime | 66 | CN 21 | 98.79 |
| Immune cells in cancer | Lifetime | 245 | CN 24 | 98.54 |
| Cancer-related molecular mechanisms research | Lifetime | 696 | CN 315 | 98.05 |
| MicroRNA in disease regulation | Lifetime | 742 | CN 276 | 97.80 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 759 | CN 47 | 98.40 |
| Glioma Diagnosis and Treatment | Lifetime | 764 | CN 11 | 97.92 |
| Biomarkers in Disease Mechanisms | Lifetime | 372 | CN 28 | 89.38 |
| Immune cells in cancer | 2021-2025 | 3 | CN 1 | 99.89 |
| Ferroptosis and cancer prognosis | 2021-2025 | 7 | CN 5 | 99.84 |
| Immune Cell Function and Interaction | 2021-2025 | 12 | CN 3 | 99.59 |
| Cancer-related molecular mechanisms research | 2021-2025 | 26 | CN 19 | 99.66 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 77 | CN 13 | 99.68 |
| Glioma Diagnosis and Treatment | 2021-2025 | 35 | CN 2 | 99.42 |
| MicroRNA in disease regulation | 2021-2025 | 92 | CN 61 | 98.49 |
| RNA modifications and cancer | 2021-2025 | 183 | CN 124 | 98.18 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 8 | CN 2 | 93.65 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 131 | CN 32 | 95.66 |
| Circular RNAs in diseases | 2021-2025 | 215 | CN 154 | 95.20 |
| Immunotherapy and Immune Responses | 2021-2025 | 592 | CN 166 | 93.52 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 692 | CN 140 | 95.80 |
| CAR-T cell therapy research | 2021-2025 | 818 | CN 89 | 95.33 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 467 | CN 202 | 90.96 |
| Immune Response and Inflammation | 2021-2025 | 185 | CN 71 | 90.15 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 980 | CN 127 | 94.04 |
| interferon and immune responses | 2021-2025 | 330 | CN 179 | 89.22 |
| Extracellular vesicles in disease | 2021-2025 | 761 | CN 452 | 91.03 |
| Single-cell and spatial transcriptomics | 2021-2025 | 577 | CN 158 | 89.75 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 570 | CN 240 | 79.02 |
| Viral-associated cancers and disorders | 2021-2025 | 910 | CN 189 | 78.05 |
| Bone Metabolism and Diseases | 2021-2025 | 691 | CN 318 | 74.57 |
| Telomeres, Telomerase, and Senescence | 2021-2025 | 440 | CN 47 | 74.07 |
| Phagocytosis and Immune Regulation | 2021-2025 | 995 | CN 432 | 64.69 |
| NF-κB Signaling Pathways | 2021-2025 | 278 | CN 102 | 60.01 |
| Signaling Pathways in Disease | 2021-2025 | 612 | CN 240 | 56.67 |
